Capricor Therapeutics (CAPR) Competitors $6.68 +0.49 (+7.92%) As of 01:29 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CAPR vs. LENZ, CVAC, CALT, AMLX, DNTH, COLL, ELVN, PGEN, NUVB, and WVEShould you be buying Capricor Therapeutics stock or one of its competitors? The main competitors of Capricor Therapeutics include LENZ Therapeutics (LENZ), CureVac (CVAC), Calliditas Therapeutics AB (publ) (CALT), Amylyx Pharmaceuticals (AMLX), Dianthus Therapeutics (DNTH), Collegium Pharmaceutical (COLL), Enliven Therapeutics (ELVN), Precigen (PGEN), Nuvation Bio (NUVB), and WAVE Life Sciences (WVE). These companies are all part of the "pharmaceutical products" industry. Capricor Therapeutics vs. Its Competitors LENZ Therapeutics CureVac Calliditas Therapeutics AB (publ) Amylyx Pharmaceuticals Dianthus Therapeutics Collegium Pharmaceutical Enliven Therapeutics Precigen Nuvation Bio WAVE Life Sciences LENZ Therapeutics (NASDAQ:LENZ) and Capricor Therapeutics (NASDAQ:CAPR) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk. Which has more volatility & risk, LENZ or CAPR? LENZ Therapeutics has a beta of 0.45, suggesting that its stock price is 55% less volatile than the S&P 500. Comparatively, Capricor Therapeutics has a beta of 0.73, suggesting that its stock price is 27% less volatile than the S&P 500. Does the media prefer LENZ or CAPR? In the previous week, Capricor Therapeutics had 2 more articles in the media than LENZ Therapeutics. MarketBeat recorded 8 mentions for Capricor Therapeutics and 6 mentions for LENZ Therapeutics. LENZ Therapeutics' average media sentiment score of 0.95 beat Capricor Therapeutics' score of 0.76 indicating that LENZ Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LENZ Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Capricor Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is LENZ or CAPR more profitable? LENZ Therapeutics has a net margin of 0.00% compared to Capricor Therapeutics' net margin of -181.71%. LENZ Therapeutics' return on equity of -25.63% beat Capricor Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets LENZ TherapeuticsN/A -25.63% -24.43% Capricor Therapeutics -181.71%-62.71%-50.82% Do institutionals and insiders believe in LENZ or CAPR? 54.3% of LENZ Therapeutics shares are owned by institutional investors. Comparatively, 21.7% of Capricor Therapeutics shares are owned by institutional investors. 6.9% of LENZ Therapeutics shares are owned by company insiders. Comparatively, 10.5% of Capricor Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has better valuation and earnings, LENZ or CAPR? Capricor Therapeutics has higher revenue and earnings than LENZ Therapeutics. LENZ Therapeutics is trading at a lower price-to-earnings ratio than Capricor Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLENZ TherapeuticsN/AN/A-$49.77M-$1.90-21.11Capricor Therapeutics$22.27M13.71-$40.47M-$1.64-4.07 Do analysts recommend LENZ or CAPR? LENZ Therapeutics presently has a consensus target price of $49.60, indicating a potential upside of 23.66%. Capricor Therapeutics has a consensus target price of $22.25, indicating a potential upside of 233.08%. Given Capricor Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Capricor Therapeutics is more favorable than LENZ Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LENZ Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Capricor Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 SummaryCapricor Therapeutics beats LENZ Therapeutics on 11 of the 16 factors compared between the two stocks. Get Capricor Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CAPR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CAPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CAPR vs. The Competition Export to ExcelMetricCapricor TherapeuticsMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$306.55M$10.35B$5.65B$10.30BDividend YieldN/A1.90%5.68%4.61%P/E Ratio-4.0920.1075.7126.17Price / Sales13.7129.50514.12169.29Price / CashN/A24.3737.5661.52Price / Book2.093.3412.926.31Net Income-$40.47M$212.47M$3.29B$270.94M7 Day Performance4.37%-2.81%-0.14%0.11%1 Month Performance1.21%-4.20%3.97%6.67%1 Year Performance-35.40%-10.87%68.37%28.91% Capricor Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CAPRCapricor Therapeutics2.3343 of 5 stars$6.68+7.9%$22.25+233.1%-32.0%$306.55M$22.27M-4.09101Analyst ForecastGap UpHigh Trading VolumeLENZLENZ Therapeutics1.445 of 5 stars$41.26-2.4%$49.60+20.2%+89.2%$1.21BN/A-21.72110CVACCureVac3.9869 of 5 stars$5.36+0.2%$6.83+27.5%+68.0%$1.20B$579.18M5.58880News CoveragePositive NewsCALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180AMLXAmylyx Pharmaceuticals1.405 of 5 stars$13.31flat$14.50+8.9%+361.1%$1.19B$87.37M-5.32200DNTHDianthus Therapeutics2.8211 of 5 stars$37.76+2.7%$61.57+63.1%+33.5%$1.18B$6.24M-11.6280Positive NewsCOLLCollegium Pharmaceutical4.0457 of 5 stars$35.64-0.3%$42.33+18.8%-7.0%$1.13B$631.45M34.27210Positive NewsELVNEnliven Therapeutics2.6227 of 5 stars$19.92+5.1%$41.20+106.8%-20.2%$1.12BN/A-9.9650Insider TradePGENPrecigen4.4202 of 5 stars$3.85+2.7%$8.25+114.3%+299.1%$1.12B$3.92M-9.17190Positive NewsNUVBNuvation Bio2.7713 of 5 stars$3.26+1.3%$7.50+129.8%+21.2%$1.10B$7.87M-5.1860Gap DownWVEWAVE Life Sciences4.4624 of 5 stars$6.90+0.1%$20.33+194.7%-17.8%$1.10B$108.30M-7.67240 Related Companies and Tools Related Companies LENZ Competitors CVAC Competitors CALT Competitors AMLX Competitors DNTH Competitors COLL Competitors ELVN Competitors PGEN Competitors NUVB Competitors WVE Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CAPR) was last updated on 9/25/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Capricor Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Capricor Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CAPR Stock Alerts